State of CDMO Quality — Q3 2026
The independent snapshot: rankings, FDA activity, GMP density, and what sponsors should watch.
Executive summary
Q3 2026 opens with the CDMO industry in a comparatively stable posture on quality but with widening capacity stratification. This report is a data-driven snapshot from CDMO Signal's platform of primary regulatory sources — FDA inspection records, EMA and MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored trade press.
Key takeaways. CDMO Signal tracks 314 CDMOs, of which 163 are fully scored across all four Signal Score pillars. The excellent tier (Signal Score ≥ 90) contains 3 CDMOs — the narrow set combining top-quartile regulatory posture, capacity depth, and financial stability. Recent FDA activity (8 inspections in the last 90 days) skews toward NAI classifications — the healthiest quarterly signal since the platform began tracking. GMP certificate density remains concentrated in the top 10 CDMOs, which collectively hold a disproportionate share of tracked EMA + MHRA authorizations.
Coverage snapshot
What this report is built on. All counts are live at the time of viewing; the platform updates FDA inspection records daily, and the composite Signal Score recomputes on the same cadence.
The industry leaderboard
The top 15 CDMOs by composite Signal Score. This list mixes pure-play viral vector specialists, integrated pharma-CDMOs, Asia-Pacific players scaling into global supply, and diversified biologics manufacturers. Signal Score does not weight modality specialization — a focused specialist and a diversified player can both rank at the top when their regulatory posture, sponsor footprint, financial stability, and capacity signals all check out.
| # | CDMO | Signal Score | Quality | Capacity |
|---|---|---|---|---|
| 1 |
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | Limited |
| 2 |
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
|
91.5 | 100.0 | — |
| 3 |
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
|
90.8 | 97.0 | — |
| 4 |
Novartis
Basel, Switzerland
|
88.3 | 90.9 | — |
| 5 |
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | — |
| 6 |
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
|
85.6 | 100.0 | — |
| 7 |
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
85.6 | 100.0 | — |
| 8 |
Aldevron
Fargo, ND
|
85.3 | 100.0 | — |
| 9 |
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
|
84.8 | 100.0 | — |
| 10 |
City of Hope (T Cell Manufacturing)
Duarte, CA
|
83.8 | 96.8 | — |
| 11 |
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | — |
| 12 |
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | — |
| 13 |
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.6 | 95.7 | — |
| 14 |
KBI Biopharma
Durham, NC · Boulder, CO
|
83.5 | 100.0 | Limited |
| 15 |
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | Expanding |
Modality leaders
Top-3 CDMOs per modality, ranked by composite Signal Score. Sponsors typically look at their specific modality first; the same CDMO can lead in one modality without being competitive in another, and specialization matters as much as scale. Click any name for the full profile including FDA inspection detail and GMP certificate list.
Signal Score distribution
How the industry stacks up across the composite Signal Score's 0–100 range. The distribution is meaningfully asymmetric — a heavy tail at the excellent and strong tiers reflects the industry's actual quality stratification. This is not a bell curve; the biopharma CDMO industry has real, measurable gaps between top-tier and long-tail providers, and Signal Score surfaces them by design.
How to read this. The Excellent tier (≥ 90) is the narrowest by design — a CDMO needs top-quartile scores across all four pillars to land there, and most reach that threshold via strong Quality Compliance combined with either broad Operations footprint or dense Capacity Intelligence. The Strong tier (80–89) is where the bulk of well-established CDMOs cluster. The Watch tier (< 60) is not a red flag on its own; it usually indicates thin regulatory data (a CDMO with a narrow public inspection record) rather than genuine quality concerns.
FDA activity — last 90 days
Recent FDA inspection outcomes across the tracked CDMO set. The classification breakdown is the most reliable near-term signal on industry quality trajectory — a NAI-heavy quarter indicates the industry is maintaining compliance under regulator scrutiny; a shift toward VAI or OAI indicates emerging quality issues that sponsors should investigate.
Recent inspections
| Date | CDMO | Site | Classification |
|---|---|---|---|
| 2026-05-29 | AGC Biologics | Bothell, Washington | ● NAI |
| 2026-05-22 | Catalent | Morrisville, North Carolina | ● VAI |
| 2026-05-22 | Bayer (Cell Therapy Mfg) | Myerstown, Pennsylvania | ● NAI |
| 2026-05-15 | Eurofins CDMO | Honolulu, Hawaii | ● NAI |
| 2026-05-07 | Thermo Fisher Scientific | Allentown, Pennsylvania | ● NAI |
| 2026-05-06 | Agilent Technologies (Oligo GMP) | Boulder, Colorado | ● NAI |
| 2026-05-04 | Bachem | Torrance, California | ● VAI |
| 2026-05-01 | Charles River Laboratories | Saint-Laurent | ● NAI |
GMP certificate density leaders
GMP certificate density — the combined count of EMA (European Medicines Agency EudraGMDP) and MHRA (UK Medicines & Healthcare products Regulatory Agency) certificates — is the most concrete objective measure of a CDMO's global regulatory posture. Every certificate represents a regulator having formally inspected and authorized a site for a specific manufacturing activity. High density indicates a deep global network with sustained regulatory engagement; it's a slow, expensive credential to accumulate, which is why it correlates strongly with commercial-scale capability.
| # | CDMO | EMA | MHRA | Total |
|---|---|---|---|---|
| 1 | Novartis | 57 | 3 | 60 |
| 2 | Catalent | 19 | 16 | 35 |
| 3 | AGC Biologics | 23 | 0 | 23 |
| 4 | FUJIFILM Diosynth Biotechnologies | 17 | 6 | 23 |
| 5 | Pfizer CentreOne | 15 | 3 | 18 |
| 6 | Takeda | 18 | 0 | 18 |
| 7 | Curia (RNA/Advanced) | 16 | 0 | 16 |
| 8 | Bayer (Cell Therapy Mfg) | 15 | 1 | 16 |
| 9 | Oxford Biomedica | 4 | 10 | 14 |
| 10 | Wacker Biotech | 13 | 0 | 13 |
Most-inspected CDMOs (all-time)
Inspection footprint is a proxy for both facility scale and depth of regulatory engagement. A CDMO with high inspection counts is either operating many sites, running many manufacturing activities, or has drawn sustained regulator attention — often all three. This list is not a quality signal on its own; the classification distribution of those inspections (NAI vs VAI vs OAI) is what actually tells the quality story, and that lives on individual CDMO profile pages.
| # | CDMO | FDA inspections |
|---|---|---|
| 1 | Novartis | 14 |
| 2 | Catalent | 11 |
| 3 | Bayer (Cell Therapy Mfg) | 8 |
| 4 | Charles River Laboratories | 8 |
| 5 | BSP Pharmaceuticals | 7 |
| 6 | Bristol Myers Squibb (CGT Mfg) | 5 |
| 7 | CCRM | 5 |
| 8 | Eurofins CDMO | 5 |
| 9 | Piramal Pharma Solutions | 5 |
| 10 | Sun Pharmaceutical Industries Ltd. | 5 |
Warning Letter footprint
Warning Letters are the most serious FDA regulatory communication and stay on the record indefinitely. This section surfaces the small set of CDMOs in our tracked universe with public Warning Letter history. A single Warning Letter is a serious event; recurring Warning Letters across multiple years are the strongest publicly available quality signal.
| # | CDMO | Warning Letters |
|---|---|---|
| 1 | Intas Pharmaceuticals | 6 |
| 2 | Catalent | 2 |
| 3 | Simtra BioPharma Solutions | 2 |
What we're watching next quarter
Three structural themes we're tracking into Q4 2026, based on the platform's data flow and monitored press.
The last 24 months have seen substantial commercial-scale capacity announcements in AAV, lentiviral vector, and mRNA manufacturing. Whether that capacity translates into validated commercial supply — versus paper capacity that never materializes — is the key operational question. We watch the Capacity Intelligence pillar for facility-opening confirmations and validated batch scale-up.
With the wave of approved ADCs (Enhertu, Trodelvy, Elahere, Tivdak) and dense clinical pipelines, ADC CDMO capacity remains a bottleneck. Expect continued M&A in the integrated ADC segment. The ADC CDMO ranking and its filter sub-paths track this.
Post-pandemic FDA inspection cadence is still not fully normalized, particularly for foreign sites. Recent NAI-heavy classifications may partially reflect the FDA prioritizing lower-risk sites for its backlog; the trajectory to watch is when OAI classifications return to their pre-2020 baseline rate, which will reset how sponsors weight inspection recency in vendor selection.
Methodology & sources
All data cited in this report is drawn from CDMO Signal's platform of primary regulatory and operational sources: FDA Data Dashboard inspection records (Establishment Inspection Reports, Form 483 observations, Warning Letters), EMA EudraGMDP and MHRA GMDP certificate registries, ClinicalTrials.gov sponsor/site records, SEC EDGAR filings, and monitored trade press. Signal Score is a 0–100 composite of four weighted pillars: Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%). CDMOs cannot pay to influence their scores; there is no sponsored placement.
For the complete methodology, weight derivations, and per-source disclosures, see cdmosignal.com/methodology. Data refreshes daily; rankings and counts in this report reflect the current platform state and update automatically.
How to cite this report
Please cite as:
CDMO Signal. "State of CDMO Quality — Q3 2026." Published 2026-07-18. Retrieved from https://cdmosignal.com/reports/state-of-cdmo-quality-2026-q3.
For journalists, analysts, or research groups: additional data extracts and methodology detail are available on request at hello@cdmosignal.com.